Promotie onderzoek

All people living with HIV need life-long treatment with antiretroviral therapy (ART). However, ART coverage in children living with HIV continues to lag behind adults and many paediatric patients in sub-Saharan Africa still do not receive optimal paediatric treatment formulations or state-of-the-art drugs. Studies of efficacy and safety of these drugs in children have lagged behind, and the full range of appropriate formulations to treat younger children are yet to be developed for both first- and second-line treatments. 
 

Het optimaliseren van de antivirale behandeling van kinderen met HIV in Afrika door verdieping in de PK/PD van deze middelen, nieuwe formuleringen en het voorspellen van de PK middels modelleren. 
 

The aim of this project is to explore the 3D printing of peadiatric medicines. 3D printing technology enables the creation of medications with a wide range of dosages, shapes, flavors, and drug combinations, all customized to meet the unique needs of individual patients and specific disease conditions. Once the optimal formulations have been developed, the 3D printed medicines will undergo clinical trials for testing. 

The aim is to present current and new strategies university hospitals can undertake to contain costs of expensive drugs using a drug life cycle approach.
 

We will study compounding medication by 3D printing technology. In this way personalized medication will become more accessable. 
First formulation studies will be executed in order to provide a stable production process. After which, the use of 3D printing will be introduced in the clinical setting. Finally, the printed medication will be tested by a clinical trial.
 

We aim to develop models for sepsis detection and therapeutic treatment personalization, using mechanistic modelling and ML/AI approaches.